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Background: Few studies have evaluated age-related predictors associated with the underuse of medications in
patients with coronary heart disease (CHD). The objective of this study was to identify age-related differences in the
factors associated with the underuse of recommended medications in patients diagnosed with acute coronary
syndrome (ACS).
Methods: From August 2009 to April 2011, we recruited 469 consecutive ACS patients from a cardiac center at a
university hospital. We divided the patients into older (65 years of age and older, n = 202) and younger groups
(younger than 65 years of age, n = 267). Data on socio-demographic characteristics, depressive symptoms, and
medication use were obtained from a telephone survey administered 18 to 24 months after hospital discharge.
Additionally, we asked the patients to provide reasons for not taking their medications.
Results: A significantly increased underuse of medication was noted in older patients compared with younger
patients, including aspirin (24.8% vs. 37.1%, p = 0.005), beta-blockers (20.3% vs. 34.8%, p = 0.001), ACE inhibitor/
angiotensin receptor blockers (27.2% vs. 36.7%, p = 0.030), and statins (21.8% vs. 29.6%, p = 0.005). Among older
patients, the factors associated with the underuse of medications included low education level (odds ratio [OR], 3.93),
greater number of comorbidities (OR, 1.64), and total number of discharge medications (OR, 1.31). The reasons provided
by older patients for not taking medication included the fact that the medication was considered to be non-essential
and the large number of medications. Among younger patients, low income (OR, 3.97) and depression (OR, 2.62) were
predictors for underuse of medication, and the reasons provided for not taking medications included high costs and
the fear of adverse effects.
Conclusions: At least one year after ACS hospital discharge, the underuse of recommended medications is related to
low education level, comorbidities, and the total number of discharge medications in elderly patients, whereas
underuse in younger patients is associated with low income and depression. The disparities related to these different
predictors may have implications for age-related interventions targeting secondary preventions in CHD patients to
improve their use of medication.
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Coronary heart disease (CHD) is the leading cause of
morbidity and mortality in China [1-3]. Urbanization,
industrialization, and population aging have resulted in a
rapid and significant increase in the prevalence of CHD
in recent decades [1]. Unstable angina (USA), Non-ST
segment elevation myocardial infarction (NSTEMI), and
ST-segment elevation myocardial infarction (STEMI) are
common manifestations of acute coronary syndrome
(ACS) and are major causes of hospitalizations [4-6]. Con-
versely, this rate has decreased over the last 3 decades be-
cause of the attention given to coronary risk factors and
improvements in clinical management [5,6]. Therefore, ef-
forts should be refocused on secondary prevention. The
secondary prevention of CHD involves managing both
lifestyle factors and physiologic parameters, often with
medications. It is well accepted that adequate treatments
with multiple evidence-based medications and vigorous
control of major risk factors in CHD patients are cost-
effective secondary strategies [7,8]. More than 40% of the
recent decline in CHD mortality has been attributed to
evidence-based medications [9]. The recommended
medications for patients who have previously experienced
an ACS episode include the concurrent use of lipid-
lowering agents, antiplatelet medications, beta-blockers,
and angiotensin-converting enzyme inhibitors (ACEI) or
angiotensin II receptor blockers (ARB) [10,11].
Despite the large amount of evidence supporting the
use of recommended medications and the development
of public policies, which have led to significant improve-
ments in ACS management and its consequences in recent
years, the underuse of optimal cardioprotective medications
is prevalent among CHD outpatients and is associated with
a broad range of adverse outcomes, including all-cause and
cardiovascular mortality, cardiovascular hospitalizations,
and revascularization procedures [12-14]. However, in
many developed countries, the rate of recommended medi-
cation use is reportedly low [9,13,15], particularly for older
patients [16]. Several studies have suggested that age-
related differences in the use of secondary medical preven-
tions are a widespread phenomenon among CHD patients
and that older patients are less likely to take recommended
medications [16-18]. However, few studies have attempted
to explain the age-related differences in the underuse of
these secondary prevention medications based on socio-
demographic factors and clinical characteristics or to evalu-
ate the differences in terms of the reasons why patients did
not take their medications.
We performed a long-term observational study with the
following objectives: 1) to better characterize the underuse
of recommended medications for secondary prevention in
Chinese ACS patients at least one year after hospital dis-
charge; 2) to determine whether age is associated with the
underuse of medications in these high-risk CHD patients;and 3) to identify differences in the factors associated with
the underuse of recommended medications between age
groups. Additionally, we explored the patients’ reasons for
not taking their recommended medications.
Methods
Study population
From August 2009 to April 2011, consecutive ACS pa-
tients were selected from a cardiac center at a university
hospital, located in Nanjing. Diagnosis of ACS is based
upon symptom history, clinical presentation, electrocar-
diogram ST-segment changes, and enzyme elevation. All
participants provided full written informed consent, and
the study was approved by the Committee of Clinical In-
vestigation at Southeast University School of Medicine.
The following exclusion criteria were applied: age older
than 85 years, age younger than 18 years, severe hearing
impairment, unintelligible speech, lack of cooperation,
delirium or severe dementia, illness that interfered with
participation, overt psychiatric illness, administration of
all medications by a caregiver, and no telephone number.
Given that the purpose of our study was to assess the
underuse of recommended medications in ACS patients
at least one year after discharge, patients were also ex-
cluded if they suffered from an ACS episode within 12
months and if they participated in other clinical trials.
In total, 697 eligible patients were identified during
the study period. Of these patients, 118 were excluded;
17 patients died before the survey was administered; 15
patients were older than 85 years of age; 54 patients par-
ticipated in other clinical trials; 9 patients had a psychi-
atric illness or cognitive decline, and 23 patients were
hospitalized for a recurrent acute coronary event during
the 12-month period before the survey was administered.
Of the 579 patients included in the study, 63 patients were
unavailable for follow-up, and 23 patients did not complete
the telephone review. An additional 24 patients refused to
respond to a telephone survey. Hence, a total of 469 pa-
tients were included in this analysis (Figure 1). We use
65 years of age and older as the definition of an older
individual because most countries have accepted this
definition of old age. With regard to anthropometric,
socioeconomic, and clinical characteristics, no statisti-
cally significant differences were noted between the re-
sponders and non-responders.
Design and data collection
While still hospitalized following their procedures, the pa-
tients were approached by a researcher who assessed their
eligibility for study enrollment. Baseline medications were
collected using medical charts and electronic medical re-
cords. The collected data included patient demographics,
past medical history, clinical characteristics, comorbidities,
inpatient treatment, medications prescribed at the time of
Figure 1 Recruitment flowchart. ACS, acute coronary syndrome.
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medications prescribed at the time of discharge, including
aspirin, beta-blockers, statins, and ACEI/ARB, were ob-
tained from the medical records. ACEI and ARB were
grouped as a single variable because they are both used
in the treatment of hypertension and congestive heart
failure, and ARB is generally administered to patients
who are intolerant of ACEI. The variable “total number
of discharge medications” was the sum of all chronic
medications mentioned by the patient at the time of dis-
charge from the hospital.
During the study period, follow-up information was ob-
tained from patients via telephone surveys conducted by
trained interviewers approximately 18 to 24 months after
discharge. The purpose of this survey was to document
the occurrence of secondary cardiovascular events, hospi-
talizations, and scheduled or unscheduled outpatient car-
diologist visits between the time of discharge and the
telephone survey. We also assessed current medication
use and depressive symptoms. At least 3 attempts to con-
tact patients were made at various times of the day. For
the purpose of this analysis, the length of time in days
from the date of discharge to the date of telephone contact
(interim period time) was taken as the number of months
post discharge.
The telephone questionnaire focused on the following
points. The first section included patient baseline charac-
teristics, such as age, sex, educational level, marital status,
income, living situation, smoking, alcohol use, medicalhistory, and depressive symptoms. To evaluate the presence
and severity of depressive symptoms, we administered the
well-validated 9-item Patient Health Questionnaire (PHQ)
[19]. Higher scores indicated more severe depressive symp-
toms. Our primary predictor variable was a single question
regarding the treatment status of aspirin, statins, beta-
blockers, and ACEI or ARB. Information regarding medica-
tion use was obtained by asking the patients to provide
their medication bottles and to respond to the question,
“What medications do you take now?” If the patients re-
plied, “none,” the reasons for not taking the medications
were explored. To perform this assessment, the patients
were asked, “Which one of the following is the reason for
not taking it?” The patients were prompted with possible
options, including being unable to afford the cost of the
medications, considering the medications to be non-
essential, having been prescribed too many medications, be-
ing concerned about adverse effects, and suffering side ef-
fects. The patients were asked to choose their reasons for
not taking the medications. More than one reason could be
recorded.
Statistical analyses
The data are presented as the mean ± standard deviation
for normally distributed data or as the median (interquar-
tile range) for skewed continuous variables. We conducted
comparisons of continuous variables using Student’s t-test
or the Mann–Whitney U test. The chi-squared test was
used to compare categorical variables between the two
groups. Associations between variables of interest and the
underuse of medication were assessed using logistic re-
gression. Significant univariate predictors were included in
multivariate logistic regression analysis. We included the
following 9 covariates in the model: age, gender, education,
insurance, income, comorbidities, PHQ scores, number of
medications at the time of discharge, and outpatient cardi-
ologist visit from the time of discharge. We performed
statistical analyses using SPSS software 16.0 (SPSS Inc.,
Chicago, IL, USA). All tests were two-sided. We consid-
ered p < 0.05 to be statistically significant.
Results
Comparison of the anthropometric, socioeconomic, and
clinical characteristics of patients in the two age groups is
presented in Table 1. The older patients were more likely
to live alone and were less likely to have completed senior
high school or higher. Compared with the younger group,
employment in the older age group was significantly lower.
Established comorbidities (congestive heart failure, diabetes
mellitus, dyslipidemia, stroke, chronic renal failure, and
chronic obstructive pulmonary disease) were more preva-
lent in the older age group. Compared with the older
group, the younger patients had significantly higher PHQ
scores. The number of discharge medications prescribed to
Table 1 Characteristics of the study patients based on age group
Overall (n = 469) 65 years of age
and older (n = 202)
Younger than 65 years
of age (n = 267)
p
Age, years 62.4 ± 9.7 71 ± 5 56 ± 6.9 < 0.001
Gender, female, n (%) 142 (30.3) 67 (33.2) 75 (28.1) 0.264
Married 442 (94.2) 187 (92.6) 255 (95.5) 0.229
Educational level
Junior high school or lower 166 (35.4) 91 (45.0) 75 (28.1) < 0.001
Senior high school 198 (42.2) 86 (42.6) 112 (41.9)
University/college 105 (22.4) 25 (12.4) 80 (30.0)
Manual laborer 48 (10.2) 26 (12.9) 22 (8.2) 0.101
Employed 178 (38) 7 (3.5) 171 (64) < 0.001
Income (Chinese yuan/month)
1,200 - 3,000 248 (52.9) 156 (77.2) 92 (34.5) < 0.001
3,000 - 5,000 166 (35.4) 27 (13.4) 139 (52.1)
≥ 5,000 55 (11.7) 19 (9.4) 36 (13.5)
Basic medical insurance* 391 (83.4) 162 (80.2) 229 (85.8) 0.109
Live alone 29 (6.2) 20 (9.9) 9 (3.4) 0.004
Currently smoking 111 (23.7) 45 (22.3) 66 (24.7) 0.538
Regular alcohol use 30 (6.4) 12 (5.9) 18 (6.7) 0.726
Depressive symptoms (PHQ score) 4 (2–7) 4 (2–6) 5 (3–7) 0.005
No. of diseased vessels 1 (1–2) 1 (1–2) 1 (1–2) 0.107
Comorbidities
Congestive heart failure 37 (7.9) 27 (13.4) 10 (3.7) < 0.001
Diabetes 103 (22.0) 57 (28.2) 46 (17.2) 0.004
Hypertension 262 (55.9) 122 (60.4) 140 (52.4) 0.086
Dyslipidemia 84 (17.9) 49 (24.3) 35 (13.1) 0.002
Cardiac dysrhythmias 31 (6.6) 18 (8.9) 13 (4.9) 0.081
Stroke 27 (5.8) 17 (8.4) 10 (3.7) 0.032
Any previous revascularization 36 (7.7) 21 (10.4) 15 (5.6) 0.054
Chronic renal failure 38 (8.1) 24 (11.9) 14 (5.2) 0.009
COPD 29 (6.2) 19 (9.4) 10 (3.7) 0.012
Gastrointestinal disease 48 (10.2) 27 (13.4) 21 (7.9) 0.052
Others 45 (9.6) 29 (14.4) 16 (6.0) 0.002
In-hospital treatment (PCI/CABG) 444 (94.7) 190 (94.1) 254 (95.1) 0.609
Time between discharge and follow-up survey, months 19.5 ± 2.6 19.3 ± 2.6 19.7 ± 2.6 0.161
Number of outpatient cardiologist visits since hospital discharge 7 (5–9) 6 (4–8) 8 (6–10) < 0.001
Rehospitalization since discharge# 0 (0–1) 0 (0–1) 0 (0–1) 0.092
Medication use at discharge
Aspirin 445 (94.9) 188 (93.1) 257 (96.5) 0.121
Beta-blocker 420 (89.6) 175 (86.6) 245 (91.8) 0.072
Statin 414 (88.3) 172 (85.1) 242 (90.6) 0.067
ACE inhibitor/ARB 319 (68.0) 135 (66.8) 184 (68.9) 0.632
Number of prescribed medications§ 6 (5–10) 8 (5–12) 5 (4–7) < 0.001
Data are represented as the number (%) of patients; *medical insurance provided by the government; STEMI, ST segment elevated myocardial infarction;
NSTEMI, non-ST segment elevated myocardial infarction; COPD, chronic obstructive pulmonary disease; CABG, coronary artery bypass graft; PCI, percutaneous
coronary intervention; ACEI, angiotensin- converting enzyme; #patient was readmitted for a cardiac catheterization, PCI, stress test, or other causes during the
interim follow-up period from hospital discharge to the date of the follow-up survey; ARB, angiotensin receptor blocker; §the number of patients using
prescribed medications, including non-recommended medications.
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patients. The younger patients were more likely to see phy-
sicians on a regular basis compared with older patients. No
between-group differences were observed in terms of mari-
tal status, insurance, smoking, number of diseased vessels,
management strategies, and rehospitalization from the
time of discharge.
Every patient in the cohort was prescribed at least one
recommended medication at hospital discharge. The ma-
jority (89.3%) of the population was prescribed three or
more recommended medications (e.g., aspirin, beta-
blockers, statin, and ACEI/ARB) at hospital discharge
(Table 1). The rate of prescribed recommended medica-
tions at hospital discharge was similar between the two age
groups (Table 1). The number of patients using 10 or more
prescribed medications, including non-recommended
medications, at the time of discharge was larger in older
patients than in younger patients (43.6% of those 65 years
of age and older and 12.4% of those younger than 65 years
of age) (p < 0.001).
At the time of the follow-up survey, 39.7% patients were
not taking any recommended medications (51.5% in the
older group and 30.7% in the younger group). Figure 2
shows the rate of recommended medication use for the
total number of patients and for each age group at the
time of the survey. Overall, the proportion of patients who
continued to use aspirin, beta-blockers, ACEI/ARB, and
statin therapy was 31.8%, 28.8%, 32.6%, and 24.7%, re-
spectively. Significantly lower medication use was noted in
older patients than in younger patients, including the use
of aspirin (24.8% vs. 37.1%, p = 0.005), beta-blockers
(20.3% vs. 34.8%, p = 0.001), ACEI/ARB (27.2% vs. 36.7%,
p = 0.030), and statins (21.8% vs. 29.6%, p = 0.005).
The reasons for not taking the recommended medica-
tions varied between age groups (Table 2). More older pa-
tients complained about taking too many medications
(48.7% vs. 17.9% for aspirin, 40.5% vs. 10.9% for beta-
blocker, and 39.2% vs. 8.9% for ACEI/ARB) or consideredFigure 2 Percentage of patients taking recommended medications ba
beta-blockers = 0.001, statins = 0.005, angiotensin-converting enzyme inhibitormedications to be non-essential (36.4% vs. 5.3% for statins,
32.7% vs. 12.6% for beta-blocker, and 37.8% vs. 7.7% for
ACEI/ARB). Among younger patients, cost (37.8% vs.
10.9% for statin, 23.0% vs. 6.0% for beta-blocker, and
29.0% vs. 6.1% for ACEI/ARB) and fear of adverse effects
(31.5% vs. 8.2% for aspirin, 37.4% vs. 7.7% for beta-blocker,
and 43.2% vs. 7.4% for ACEI/ARB) were common reasons
for not taking medications.
Overall, age was an independent predictor of medication
underuse (OR = 1.05, 95% CI, 1.02 - 1.08, P = 0.002), even
after adjusting for gender, education, income, insurance,
comorbidities, PHQ scores, and the number of medica-
tions at discharge. In subgroups, low educational level,
more comorbidities, and high numbers of discharge medi-
cations exhibited an independent and a positive impact
on medication underuse in older patients, whereas low
income and higher PHQ scores were predictors for
medication underuse in younger patients (Table 3).
Additionally, an inverse relationship between older age
and recommended medication use was noted in both
groups (Table 3).
Discussion
Overall, the proportions of ACS patients who continued
to use aspirin, beta-blockers, ACEI/ARB, and statins at
least one year after discharge were 31.8%, 28.8%, 32.6%,
and 24.7%, respectively. Despite the fact that the number
of prescribed medications at hospital discharge was high
for the ACS patients, the rate of medication use reduced
obviously one year after discharge. The treatment rate of
recommended medications in the present survey is low
compared with that employed in Western countries [9]
or other surveys in mainland China [3,20]. However, a
comparison of these reports must be viewed with cau-
tion. Considerable differences exist between the present
study and other studies, particularly with regard to the
population selection criteria, ascertainment of medica-
tion use, and time points studied. Our study populationsed on age at the time of the survey. (P-value: aspirin = 0.005,
[ACEI]/angiotensin receptor blocker [ARB] = 0.030, between age groups).
Table 2 Reasons cited by patients who were not taking the recommended medications, by age group
Reasons 65 years of age and older Younger than 65 years
Aspirin Statin Beta-blocker ACEI/ARB Aspirin Statin Beta-blocker ACEI/ARB
n (%)
Too expensive 11 (7.0) 18 (10.9) 10 (6.0) 9 (6.1) 21 (12.5) 71 (37.8) 40 (23) 49 (29.0)
Too many medications 77 (48.7) 47 (28.5) 68 (40.5) 58 (39.2) 30 (17.9) 18 (9.6) 19 (10.9) 15 (8.9)
Consider medications non-essential 32 (20.3) 60 (36.4) 55 (32.7) 56 (37.8) 28 (16.7) 10 (5.3) 22 (12.6) 13 (7.7)
Afraid of adverse effects 13 (8.2) 17 (10.3) 13 (7.7) 11 (7.4) 53 (31.5) 63 (33.5) 65 (37.4) 73 (43.2)
Side effects 16 (10.1) 14 (8.5) 15 (8.9) 8 (5.4) 16 (9.5) 16 (8.5) 20 (11.5) 12 (7.1)
Others 9 (5.7) 9 (5.5) 7 (4.2) 6 (4.1) 20 (11.9) 10 (5.3) 8 (4.6) 7 (4.1)
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.
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tients at least one year after hospital discharge, whereas
the study subjects in other reports were selected from
outpatient departments [3], which appear to underesti-
mate the treatment rates of these medications because
the patients who discontinued treatment may not visit
the outpatient departments of hospitals. Additionally, in
prior investigations, a subsequent ACS episode occurred
in most study patients within 6 months to 1 year [20]. Ac-
cording to American Heart Association (AHA) guidelines,
dual antiplatelet therapy consisting of aspirin and a thie-
nopyridine agent, such as clopidogrel, should be adminis-
tered for at least a full year and perhaps even longer in
cases of certain stent placements in patients without a
major risk for bleeding [21]. Thus, Studying consecutive
patients may explain why the patients in our study, whose
recent ACS episodes occurred after one year, were less
likely to receive the recommended medical therapies.
In agreement with a previous report [16], the older pa-
tients in our study reported significantly reduced uses ofTable 3 Multivariate logistic regression models analysis for n
the survey
65 years of age an
OR (95% CI)
Age (per year) 1.12 (1.02 - 1.22)
Gender (vs. male)
Female 0.32 (0.13 - 0.79)
Education (vs. senior high school or higher)
Junior high school or lower 3.93 (1.65 - 9.32)
Income (vs. medium income or higher)
Low income 0.58 (0.22 - 1.51)
Insurance (vs. basic medical insurance)
Lack of insurance 2.65 (0.89 - 7.86)
Number of comorbidities 1.64 (1.12 - 2.39)
PHQ scores 0.97 (0.87 - 1.08)
Number of medications* 1.31 (1.11 - 1.55)
Number of outpatient cardiologist visits 1.16 (0.98 - 1.38)
*Number of prescribed medications at time of discharge; PHQ, Patient Health Questrecommended medications, even after adjusting for
other co-factors, such as total number of discharge med-
ications, education, and income. More importantly, this
study identified age-related disparities in the factors as-
sociated with the underuse of recommended medica-
tions in CHD patients.
Low education level is correlated with medication under-
use in older patients. This finding agrees with other studies
demonstrating that low education and low health literacy
are correlated with medication non-adherence [9]. Low
educational status may indicate limited financial resources
for medications or may reflect lower health literacy. Makar-
yus et al. reported that < 50% of patients could list all their
medications and even fewer could recall the purpose of
their medications at the time of hospital discharge [22]. Pa-
tients often delay filling prescriptions and have difficulty
understanding medication regimens after hospital discharge
[23]. Similarly, we observed that the majority of elderly pa-
tients considered their medications to be non-essential or
that they lacked knowledge of the medications. Ineffectiveot taking any recommended medications at the time of
d older Younger than 65 years
p OR (95% CI) p
0.015 1.11 (1.03-1.19) 0.008
0.013 0.95 (0.35 - 2.58) 0.921
0.002 2.69 (0.86 - 8.46) 0.088
0.264 3.97 (1.47 - 10.75) 0.007
0.080 2.58 (0.75 - 8.85) 0.131
0.011 0.85 (0.39 - 1.84) 0.686
0.570 2.62 (2.03 - 3.38) < 0.001
0.001 0.99 (0.70 - 1.42) 0.989
0.086 1.02 (0.85 - 1.23) 0.822
ionnaire.
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CHD patients can further compromise a patient’s under-
standing of his or her disease, its potential complications,
and the importance of the prescribed medication [24]. An-
other possible explanation is that low education status may
be associated with lower understanding of the benefits of
continued medication use.
In the present study, cardiovascular-related comorbid
conditions and other chronic illness were more prevalent
in older patients. Conditions that are asymptomatic and
chronic in nature and require long-term therapy are also
associated with low medication use [9]. Older patients
may have more severe diseases or comorbidities and
were also more likely to be prescribed more evidence-
based therapies. Polypharmacy continues to evolve, and
new and synergic therapies for heart disease continue to
be developed. A high number of concurrent medications
were also a primary cause of medication underuse in eld-
erly patients. Older patients more often reported not tak-
ing the recommended medications because of the large
number of discharge medications. This result is consistent
with a prior report indicating that as the total number of
medications prescribed at the time of discharge increased,
patient adherence to the cardiac regimen decreased [25].
This finding indicates that the complexity of the regimen
can impact medication use. Thus, chronic disease man-
agement programs should consider all of the medications
that patients are taking and reduce complexity by address-
ing multiple dosing frequencies whenever possible [26].
Among younger patients, high cost was an important
reason for not taking medication. Cost issues have been
identified as a major barrier to medication use [25,27].
These analyses have demonstrated that disadvantaged fi-
nancial status, as indicated by monthly incomes, was
strongly associated with low medication use. Despite the
rapid development of initiatives in mainland China to
improve health insurance coverage [28], treatment costs
are likely to remain an important predictor of low treat-
ment rates. Considerable out-of-pocket medical costs are
even encountered by patients with basic health insurance
coverage and are an even great issue for patients with
long-term treatments based on polypharmacy. The cost
associated with hospitalization and discharge medications
represents an unanticipated expense that can serve as a
substantial burden, particularly for younger patients on
fixed incomes. Furthermore, younger patients often have
children and elderly parents to support and homes to
maintain. Thus, chronic illnesses and medical expendi-
tures could significantly reduce the financial resources of
households [29]. It is unsurprising that even employed
and insured patients are unable to keep up with increasing
costs. Our findings reveal a major barrier for the medical
care of patients at high risk for developing CHD in main-
land China. Younger patients, particularly low-incomepatients with limited access to medical insurance, as de-
fined in this study, represent a large portion of the popula-
tion of China. Clearly, improvements in medical care for
high-risk younger CHD patients in China will depend on
increasing the affordability of essential medications, which
could be addressed by either increased access to medical
insurance, reduced medical care costs, or increased in-
come for younger patients.
Depression is widely associated with heart disease.
One in three ACS patients meet the criteria for minor
depression [30]. We noted that younger patients with
higher PHQ scores, indicative of depression, were asso-
ciated with medication underuse. Specifically, the devel-
opment of ischemic heart disease and related events may
produce more dissatisfaction, sadness, and disappointment
in a younger patient compared with an older patient who
has become accustomed to chronic illness. Depression has
been established as a risk factor for morbidity and mortal-
ity in CHD patients [31] and can substantially affect medi-
cation use [32], which is an important confounder that
must be monitored and measured. Even mild depression
is sufficient to dramatically alter compliance with essential
therapy. A study of patients with ACS found that the non-
adherence rate in patients without depression was 15%
and increased to 30% in those with mild depression. Pa-
tients with moderate-to-severe depression were only
slightly less adherent (37%), which suggests that the pres-
ence or absence of depression is far more important for
medication use than the degree of depression [32,33].
Based on these results, the mental health of patients con-
tributes to the non-use of recommended medications. In
contrast, depression improvements in cardiac patients
were associated with improved medication use [34], indi-
cating that the early diagnosis and treatment of depression
is important in CHD patients.
Approximately 50% of the younger patients also re-
ported being concerned about the adverse effects of their
medications. The patients’ perceptions of adverse effects
contributed significantly to their decisions regarding medi-
cation use. Previous studies have indicated that side effects
are a common patient-reported reason for discontinuing
the use of statin medications [35,36]. A greater number of
younger patients reported the discontinuation of beta-
blockers due to feeling worse or not believing the medica-
tion was helping compared with the older age group.
Various reports have indicated reduced adherence to
beta-blockers use based on side effects, including sexual
dysfunction [37], depression, and fatigue [38], which may
be more notable in the younger group. Regardless of
whether a patient’s perception of medication-induced side
effects is objective and causal or a consequence of height-
ened awareness, it is important to address these concerns
equally because patient perception, and not reality, leads
to the underuse of recommended medications. Although
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http://www.biomedcentral.com/1471-2261/14/127younger patients in this study see physicians on a more
regular basis, in an overtaxed health care system in which
clinicians see a large volume of patients without resources
to meet individual patient needs, the amount of time a
clinician spends with a patient may be insufficient to prop-
erly assess and understand his medication-taking behav-
iors [24]. Thus, it is critical that adverse effect profiles are
considered when prescribing medications and are dis-
cussed with the patient before the initial prescription and
at every visit thereafter.
Several limitations must be considered in interpreting
the results of the present study. The most significant
limitation is that our study sample had a strong local
geographical limitation. We also had a small study popu-
lation, and our participants were recruited from a single
center with a stable population. Although this factor
may limit the generalizability of results to the wider
Chinese population, the findings are likely to accurately
reflect the situations within urban centers. Second, our
study relied on patients’ self-reported medication use.
Self-report measures can be biased by inaccurate patient
recall or by social desirability, whereby patients report
an overly optimistic estimation of medication use to
their health providers. However, investigations that have
used self-reporting to assess medication use have proven
to be reliable and correlate well with pill count and elec-
tronic pill bottle monitoring [9,39]. Third, we excluded
very old patients from our study population because pa-
tients older than 85 years of age were substantially less
likely to receive these recommended medications than
younger patients. Indeed, specific evidence regarding the
efficacy and cost-effectiveness of the study medications
in very old patients is lacking. In general, old patients
have been excluded from participating in all efficacy tri-
als in which current clinical practice recommendations
are based. Ultimately, the categorization of younger or
older patients based on an age less than 65 years of age
versus 65 years of age and older is arbitrary. Although
there are commonly used definitions of old age, no gen-
eral agreement on the age at which a person is consid-
ered old exists. Fourth, we cannot provide insight into
post-discharge actions, such as prescribing recom-
mended medications during a subsequent outpatient
visit. However, a key message that emerges from a previ-
ous report is that the extent to which the medicine-
taking behavior of individuals is influenced by physicians
is substantial [40]. Existing research suggests that adher-
ence to cardiac medications is improved by complete
hospital discharge recommendations, particularly if phy-
sicians encourage their patients to obtain their medica-
tions and provide drug counseling [41,42]. Fifth, we did
not assess specific contraindications to medications; we
only assessed the use of a specific medication if it was
prescribed at discharge, suggesting that the patients werechronically taking the medications. Finally, although
every effort was made to obtain information for all pa-
tients at the time of follow-up, information was available
for only 81% of the patients. The limitations of this study
must be considered when interpreting the results.
Conclusions
At least one year after ACS hospital discharge, the under-
use of medications in elderly patients is related to low
education level, comorbidities, and a high total number of
discharge medications; in younger patients, it is related to
low-income levels and depression. The findings of the
present study can be used to guide the development of
age-related strategies to improve medication use for sec-
ondary prevention among CHD patients.
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